Comparative Pharmacology
Head-to-head clinical analysis: PREDNISOLONE EYE DROPS versus PREDSULFAIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PREDNISOLONE EYE DROPS versus PREDSULFAIR.
Prednisolone Eye Drops vs PREDSULFAIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression and suppressing inflammatory mediators such as prostaglandins and leukotrienes.
PREDSULFAIR is a combination of prednisolone (corticosteroid) and sulfacetamide (sulfonamide antibiotic). Prednisolone suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis. Sulfacetamide inhibits bacterial dihydropteroate synthase, blocking folate synthesis.
Instill 1-2 drops into the conjunctival sac of the affected eye(s) four times daily. In severe cases, dosing may be initiated with 1-2 drops every 1-2 hours and tapered upon improvement.
Prednisolone 0.5-1 mg/kg orally once daily, maximum 60 mg/day; Sulfasalazine 500 mg orally twice daily, increased by 500 mg weekly to maintenance 2-3 g/day in divided doses.
None Documented
None Documented
Plasma: 2-4 hours; tissue effects persist 18-36 hours. Clinically, duration of adrenal suppression may exceed plasma half-life.
Prednisolone: 2.1–3.5 hours (plasma); biological half-life 12–36 hours (duration of HPA axis suppression). Sulfafurazole: 3–6 hours (normal renal function), prolonged to 12–24 hours in renal impairment.
Renal (primarily as metabolites): ~70% after oral dose; unchanged drug: <20%. Biliary/fecal: minor.
PREDSULFAIR is a fixed-dose combination of prednisolone and sulfafurazole. Prednisolone is primarily metabolized hepatically; inactive metabolites are excreted renally (<30% unchanged). Sulfafurazole is acetylated and glucuronidated; parent drug and metabolites are excreted renally (≥90%, with 15-30% unchanged). Biliary/fecal elimination is minimal for both components (<5%).
Category A/B
Category C
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid/Sulfonamide Combination